跳至主要内容
临床试验/NCT01515696
NCT01515696已完成4 期

Impact of Oral Application of Gastrografin on the Meconium Evacuation in Very Low Birth Weight Infants- a Phase 4 Study

Nadja Haiden,MD0 个研究点目标入组 96 人开始时间: 2007年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
96
主要终点
Time to Complete Meconium Evacuation in Days

研究概览

简要总结

Gastrografin is a radiopaque contrast agent for the gastrointestinal tract (GIT) which can be applied orally or rectally. In neonatal intensive care, Gastrografin is used to detect otherwise radiologically invisible perforations or an insufficient GIT anastomosis after surgery. Furthermore it is used for the treatment of meconium ileus. Gastrografin has a strong osmotic effect and leads to water influx into the intestine lumen. Thereby the peristaltic movement is accelerated and the premature infant excretes stool during the hours following application. Therefore Gastrografin might be effective to mobilize meconium from small bowel and deep parts of the colon. The investigators hypothesized that enteral application of Gastrografin accelerates meconium evacuation in premature infants, and thereby enhances feeding tolerance in this population.

详细描述

In premature infants the establishment of proper gastrointestinal function is challenging and often associated with delayed meconium passage. Meconium evacuation depends on gestational age and birthweight: the more immature an infant is, the later meconium passage starts and the longer meconium passage lasts. The mean duration of meconium evacuation in premature infants with a gestational age below 30 weeks is 8 days, while mature infants excrete their meconium in 2 days. The obstruction of deep intestinal segments by tenacious, sticky meconium frequently leads to gastric residuals, a distended abdomen and delayed food passage. The time lag to full enteral feedings is extended, the probability to acquire infections due to intravenous access for parenteral nutrition increases and the hospital stay of the infant is prolonged. However, the relation between meconium passage and feeding tolerance remains controversial. While one study showed that there is little concordance between first meconium passage and feeding tolerance, an other one showed that rapid and complete excretion of meconium is crucial for oral feeding tolerance and has a positive effect on it. Recently, the investigators performed a prospective randomized trial to determine, whether repeated prophylactic applications of small volume glycerin enemas accelerate passage of meconium in very low birth weight (VLBW) infants. Disappointingly, application of enemas did not accelerate meconium evacuation. A possible reason for the ineffectiveness of glycerin enemas is that the volume used was too small to mobilize tenacious meconium sufficiently from the colon and small bowel.

Gastrografin is a radiopaque contrast agent for the gastrointestinal tract (GIT) which can be applied orally or rectally. In neonatal intensive care, Gastrografin is used to detect otherwise radiologically invisible perforations or an insufficient GIT anastomosis after surgery. Furthermore it is used for the treatment of meconium ileus. Gastrografin has a strong osmotic effect and leads to water influx into the intestine lumen. Thereby the peristaltic movement is accelerated and the premature infant excretes stool during the hours following application. Therefore Gastrografin might be more effective to mobilize meconium from small bowel and deep parts of the colon. The investigators hypothesized, that enteral application of Gastrografin accelerates meconium evacuation in premature infants, and thereby enhances feeding tolerance in this population. The objective of the present study is to determine whether the enteral application of the osmotic contrast agent Gastrografin® accelerates complete meconium excretion and improves feeding tolerance in very low birth weight infants.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
— 至 24 Hours(Child)
性别
All
接受健康志愿者

入选标准

  • premature infants with a birthweight < 1500g and a gestational age < 32 weeks

排除标准

  • major congenital disorders
  • chromosomal aberrations
  • systemic metabolic disease and
  • pre-existing gastrointestinal abnormalities (i.e. Morbus Hirschsprung)
  • pre-existing conditions of severe hypotension

研究组 & 干预措施

Gastrografin

Active Comparator

infants receive 3ml/kg Gastrografin + 6ml/kg sterile water

干预措施: Gastrografin (Drug)

Sterile water

Placebo Comparator

infants receive 9ml/kg sterile water

干预措施: Sterile water (Drug)

结局指标

主要结局

Time to Complete Meconium Evacuation in Days

时间窗: days of life until until the complete meconium evacuation from birth up to 40 days of life

Time to complete meconium evacuation in days of life until the complete meconium evacuation from birth up to 40 days of life

次要结局

  • Feeding Tolerance- Full Enteral Feedings(days of life from birth until an infant tolerates en enteral feeding volume of 140 ml/kg)

研究者

发起方
Nadja Haiden,MD
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Nadja Haiden,MD

Assoc.Prof.MD.

Medical University of Vienna

相似试验

Impact of Oral Application of Gastrografin on the... | 临床试验